XML 37 R25.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Data (Tables)

9 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.

			Three Months Ended June 30,
(Millions of dollars)			2025																		2024
			United States						International						Total						United States						International						Total
Medical
Medication Delivery Solutions			$	680					$	452					$	1,132					$	670					$	453					$	1,123
Medication Management Solutions			709						179						888						680						160						840
Pharmaceutical Systems			178						451						629						158						437						594
Advanced Patient Monitoring			176						102						278						—						—						—
Total segment revenues			$	1,743					$	1,184					$	2,927					$	1,508					$	1,050					$	2,558
Life Sciences
Specimen Management (a)			$	240					$	230					$	470					$	239					$	228					$	467
Diagnostic Solutions (a)			154						271						425						167						263						429
Biosciences			145						213						358						141						222						363
Total segment revenues			$	539					$	714					$	1,254					$	546					$	714					$	1,260
Interventional
Surgery			$	294					$	101					$	395					$	283					$	93					$	376
Peripheral Intervention			271						241						512						263						225						488
Urology and Critical Care			334						88						422						297						78						375
Total segment revenues			$	898					$	430					$	1,328					$	844					$	396					$	1,240
Other (b)			$	—					$	—					$	—					$	(6)					$	(62)					$	(67)
Total Company revenues			$	3,181					$	2,328					$	5,509					$	2,891					$	2,098					$	4,990

(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.

(b)    Represents the recognition of accruals related to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.

			Nine Months Ended June 30,
(Millions of dollars)			2025																		2024
			United States						International						Total						United States						International						Total
Medical
Medication Delivery Solutions			$	2,060					$	1,313					$	3,373					$	1,971					$	1,310					$	3,282
Medication Management Solutions			2,030						470						2,500						1,883						475						2,359
Pharmaceutical Systems			431						1,191						1,622						442						1,154						1,596
Advanced Patient Monitoring			490						317						806						—						—						—
Total segment revenues			$	5,012					$	3,290					$	8,302					$	4,297					$	2,940					$	7,237
Life Sciences
Specimen Management (a)			$	721					$	667					$	1,387					$	708					$	664					$	1,372
Diagnostic Solutions (a)			556						783						1,340						578						787						1,365
Biosciences			440						631						1,071						426						689						1,115
Total segment revenues			$	1,717					$	2,081					$	3,798					$	1,712					$	2,139					$	3,852
Interventional
Surgery			$	885					$	288					$	1,173					$	851					$	273					$	1,124
Peripheral Intervention			793						673						1,466						762						669						1,431
Urology and Critical Care			962						249						1,211						930						234						1,165
Total segment revenues			$	2,640					$	1,209					$	3,849					$	2,543					$	1,177					$	3,720
Other (b)			$	—					$	—					$	—					$	(6)					$	(62)					$	(67)
Total Company revenues			$	9,369					$	6,581					$	15,949					$	8,546					$	6,195					$	14,741

(a)    During the first quarter of fiscal year 2025, Life Sciences split its former Integrated Diagnostic Solutions organizational unit into two units to better align BD resources with the distinct needs of each business.

(b)    Represents the recognition of accruals related to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to the Company’s reportable segments and these matters are further discussed in Note 5.

Financial Information for Company's Segments

Segment income for the three and nine-month periods was as follows:

			Three Months Ended June 30,												Nine Months Ended June 30,
(Millions of dollars)			2025						2024						2025						2024
Income Before Income Taxes
Medical (a)			$	880					$	753					$	1,922					$	1,950
Life Sciences			391						387						1,152						1,174
Interventional			376						365						1,155						1,044
Total Segment Operating Income			1,647						1,505						4,229						4,168
Integration, restructuring and transaction expense			(97)						(112)						(279)						(288)
Net interest expense			(147)						(89)						(425)						(265)
Other unallocated items (b)			(701)						(804)						(2,154)						(2,124)
Total Income Before Income Taxes			$	703					$	500					$	1,371					$	1,491

(a)The amount for the nine months ended June 30, 2025 included charges recorded to Cost of products sold of $98 million to adjust estimated future product remediation costs and charges of $336 million due to a fair value step-up adjustment relating to Advanced Patient Monitoring's inventory on the acquisition date.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration